AU5848794A - Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use - Google Patents

Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use

Info

Publication number
AU5848794A
AU5848794A AU58487/94A AU5848794A AU5848794A AU 5848794 A AU5848794 A AU 5848794A AU 58487/94 A AU58487/94 A AU 58487/94A AU 5848794 A AU5848794 A AU 5848794A AU 5848794 A AU5848794 A AU 5848794A
Authority
AU
Australia
Prior art keywords
hiv
immunodeficiency virus
human immunodeficiency
vaccine use
gene mutants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58487/94A
Inventor
David J. Looney
Flossie Wong-Staal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU5848794A publication Critical patent/AU5848794A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU58487/94A 1993-02-05 1993-12-13 Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use Abandoned AU5848794A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1431893A 1993-02-05 1993-02-05
US014318 1993-02-05
PCT/US1993/012088 WO1994017825A1 (en) 1993-02-05 1993-12-13 Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use

Publications (1)

Publication Number Publication Date
AU5848794A true AU5848794A (en) 1994-08-29

Family

ID=21764755

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58487/94A Abandoned AU5848794A (en) 1993-02-05 1993-12-13 Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use

Country Status (2)

Country Link
AU (1) AU5848794A (en)
WO (1) WO1994017825A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026361A1 (en) * 1994-03-25 1995-10-05 Biomolecular Research Institute Ltd. Vpr AND Vpx PROTEINS OF HIV

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015661A (en) * 1994-02-14 2000-01-18 The Macfarlane Burnet Centre For Medical Research Limited Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR
IL112636A0 (en) * 1994-02-14 1995-05-26 Macfarlane Burnet Ctre Med Res Non-pathogenic strains of hiv-1
WO1996032494A1 (en) 1995-04-14 1996-10-17 University Of Alabama Research Foundation Fusion protein delivery system and uses thereof
WO1997032983A1 (en) * 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US6555342B1 (en) 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US7067134B1 (en) 1998-08-12 2006-06-27 University Of Western Ontario HIV vaccine
US7608273B2 (en) 1998-08-12 2009-10-27 University Of Western Ontario Recombinant lentivirus encoding modified GP 120 signal sequences
DK1105498T3 (en) * 1998-08-12 2009-08-31 Univ Western Ontario HIV vaccine
US6764676B1 (en) * 1998-08-24 2004-07-20 Pfizer Inc. Compositions and methods for protecting animals from lentivirus-associated disease such as feline immunodeficiency virus
WO2002020571A2 (en) * 2000-09-08 2002-03-14 Biomerieux B.V.A. Attenuated hiv strains and use thereof
EP1283272B1 (en) * 2001-08-08 2013-11-13 Janssen R&D Ireland Methods and means for assessing HIV envelope inhibitor therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491930B1 (en) * 1990-07-12 1997-01-15 The President And Fellows Of Harvard College Primate lentivirus vaccines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026361A1 (en) * 1994-03-25 1995-10-05 Biomolecular Research Institute Ltd. Vpr AND Vpx PROTEINS OF HIV

Also Published As

Publication number Publication date
WO1994017825A1 (en) 1994-08-18

Similar Documents

Publication Publication Date Title
AU5726694A (en) Human immunodeficiency virus decoy
AU7351591A (en) Seroreactive epitopes of human papillomavirus (HPV) 16 proteins
AU6816194A (en) Methods and materials for treatment of individuals infected with intracellular infectious agents
AU1259288A (en) Fluorinated nucleosides: method for their preparation and use as drugs against the human acquired immunodeficiency syndrome (aids)
AU4028895A (en) Vaccine and treatment method of Human Immunodeficiency Virus
ZA936592B (en) Nutrition for persons infected with human immunodeficiency virus
AU7973994A (en) Combination therapy for hiv infection
AU5848794A (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
AU1224100A (en) Reference clones and sequences for non-subtype b isolates of human immunodeficiency virus type 1
AU7621291A (en) Seroreactive epitopes on proteins of human papillomavirus (HPV) 18
EP0853662A4 (en) Novel replication competent human immunodeficiency virus type 2 (hiv-2) proviral clone designated hiv-2kr
AU8900691A (en) Hiv marker/aids vaccine
AU1463992A (en) Methods and pharmaceutical compositions for inhibiting protease from human immunodeficiency virus
AU1192892A (en) Pharmaceutical preparation of antistress, stress-preventive and nootropic action
AU7677891A (en) Inhibition of disease associated with immunodeficiency virus infection
AU7465696A (en) Synthetic vaccine for protection against human immunodeficiency virus infection
AU7212694A (en) Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
AU6962894A (en) Compositions and methods for inhibiting replication of human immunodeficiency virus-1
AU3836489A (en) Treatment of immunodeficiency
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AU5836390A (en) Human lymphoma-associated virus
AU3557889A (en) Protective peptides derived from human immunodeficiency virus-1 gp160
AU9179891A (en) Hiv reverse transcriptase vaccine
AU7516494A (en) Oligomers for modulating human immunodeficiency virus
AU6877991A (en) A method of inactivating human immunodeficiency virus